# Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects

> **NCT00562250** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 11 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Glimepiride
- **DRUG:** Dapagliflozin + Glimepiride

## Key facts

- **NCT ID:** NCT00562250
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2016-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00562250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00562250, "Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00562250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*